Johnson & Johnson announces major commitment to speed Ebola vaccine development
Johnson & Johnson announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The company is closely collaborating with the WHO, NIAID, and others. October 22, 2014